Moreover, the downregulation of the pump involved in drug resistance, combining monotherapy with P-gp inhibitors, and bypassing of pumps related to drug efflux are common nanotechnology methods that could be used to overcome the MDR problem in AD treatment. This evidence concerns the gene PGP and Alzheimer disease.